Literature DB >> 22444158

Sources of tissue factor that contribute to thrombosis after rupture of an atherosclerotic plaque.

A Phillip Owens1, Nigel Mackman.   

Abstract

Hyperlipidemia leads to the formation of oxidized LDL (oxLDL), vessel dysfunction, atherosclerotic disease, and ultimately to plaque rupture and thrombosis. OxLDL induces tissue factor (TF) expression in various cell types, including monocytes and macrophages. High levels of TF are present in atherosclerotic plaques and this represents that major source of TF that triggers thrombosis after plaque rupture. In addition, increased levels of "circulating TF" are observed in hyperlipidemic animals and patients. This is due to induced TF expression in monocytes and release of monocyte-derived, TF(+) microparticles, which represents a minor source of TF that likely contributes to thrombosis after plaques rupture. This review will summarize the connections between hyperlipidemia and TF expression within atherosclerotic plaques and circulating monocytes, as well as its inhibition by statins.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22444158      PMCID: PMC5885765          DOI: 10.1016/j.thromres.2012.02.026

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  66 in total

1.  Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT.

Authors:  Valery N Bochkov; Diana Mechtcheriakova; Marcus Lucerna; Joakim Huber; Roland Malli; Wolfgang F Graier; Erhard Hofer; Bernd R Binder; Norbert Leitinger
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

2.  Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.

Authors:  A Phillip Owens; Freda H Passam; Silvio Antoniak; Stephanie M Marshall; Allison L McDaniel; Lawrence Rudel; Julie C Williams; Brian K Hubbard; Julie-Ann Dutton; Jianguo Wang; Peter S Tobias; Linda K Curtiss; Alan Daugherty; Daniel Kirchhofer; James P Luyendyk; Patrick M Moriarty; Shanmugam Nagarajan; Barbara C Furie; Bruce Furie; Douglas G Johns; Ryan E Temel; Nigel Mackman
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

3.  Use of statins and the subsequent development of deep vein thrombosis.

Authors:  J G Ray; M Mamdani; R T Tsuyuki; D R Anderson; E L Yeo; A Laupacis
Journal:  Arch Intern Med       Date:  2001-06-11

4.  Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis.

Authors:  S Colli; S Eligini; M Lalli; M Camera; R Paoletti; E Tremoli
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-02       Impact factor: 8.311

5.  Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol.

Authors:  Galina K Sukhova; J Koudy Williams; Peter Libby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-09-01       Impact factor: 8.311

Review 6.  Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy.

Authors:  Daniel Steinberg
Journal:  J Lipid Res       Date:  2006-04-03       Impact factor: 5.922

7.  Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1.

Authors:  Katrin Schafer; Katja Müller; Anneke Hecke; Emmanuelle Mounier; Julia Goebel; David J Loskutoff; Stavros Konstantinides
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-09-25       Impact factor: 8.311

8.  Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice.

Authors:  Arunima Ghosh; Wei Li; Maria Febbraio; Ricardo G Espinola; Keith R McCrae; Erin Cockrell; Roy L Silverstein
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

9.  Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation.

Authors:  Florian Bea; Erwin Blessing; Monica I Shelley; Jennifer M Shultz; Michael E Rosenfeld
Journal:  Atherosclerosis       Date:  2003-04       Impact factor: 5.162

10.  Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2.

Authors:  Tiina T Tuomisto; Henri Lumivuori; Emilia Kansanen; Sanna-Kaisa Häkkinen; Mikko P Turunen; Johannes V van Thienen; Anton J Horrevoets; Anna-Liisa Levonen; Seppo Ylä-Herttuala
Journal:  Cardiovasc Res       Date:  2008-01-10       Impact factor: 10.787

View more
  9 in total

1.  Protective and detrimental effects of neuroectodermal cell-derived tissue factor in mouse models of stroke.

Authors:  Shaobin Wang; Brandi Reeves; Erica M Sparkenbaugh; Janice Russell; Zbigniew Soltys; Hua Zhang; James E Faber; Nigel S Key; Daniel Kirchhofer; D Neil Granger; Nigel Mackman; Rafal Pawlinski
Journal:  JCI Insight       Date:  2016-07-21

2.  Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection.

Authors:  Netanya G Sandler; Xinyan Zhang; Ronald J Bosch; Nicholas T Funderburg; Andrew I Choi; Janet K Robinson; Derek M Fine; Robert W Coombs; Jeffrey M Jacobson; Alan L Landay; Daniel C Douek; Randall Tressler; Sarah W Read; Cara C Wilson; Steven G Deeks; Michael M Lederman; Rajesh T Gandhi
Journal:  J Infect Dis       Date:  2014-05-26       Impact factor: 5.226

3.  Rose Bengal Photothrombosis by Confocal Optical Imaging In Vivo: A Model of Single Vessel Stroke.

Authors:  Lora Talley Watts; Wei Zheng; R Justin Garling; Victoria C Frohlich; James Donald Lechleiter
Journal:  J Vis Exp       Date:  2015-06-23       Impact factor: 1.355

Review 4.  Role of tissue factor in atherothrombosis.

Authors:  A Phillip Owens; Nigel Mackman
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

5.  PARP-14 combines with tristetraprolin in the selective posttranscriptional control of macrophage tissue factor expression.

Authors:  M Bilal Iqbal; Michael Johns; Jun Cao; Yu Liu; Sheng-Chun Yu; Gareth D Hyde; Michael A Laffan; Francesco P Marchese; Sung Hoon Cho; Andrew R Clark; Felicity N Gavins; Kevin J Woollard; Perry J Blackshear; Nigel Mackman; Jonathan L Dean; Mark Boothby; Dorian O Haskard
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

6.  The Impact of Lipoprotein-Associated Oxidative Stress on Cell-Specific Microvesicle Release in Patients with Familial Hypercholesterolemia.

Authors:  M H Nielsen; H Irvine; S Vedel; B Raungaard; H Beck-Nielsen; A Handberg
Journal:  Oxid Med Cell Longev       Date:  2016-01-27       Impact factor: 6.543

7.  Preventive Effects of Neuroprotective Agents in a Neonatal Rat of Photothrombotic Stroke Model.

Authors:  Yoon Young Yi; Hyo Jung Shin; Seung Gyu Choi; Joon Won Kang; Hee-Jung Song; Sung Koo Kim; Dong Woon Kim
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

8.  Protective effect of microRNA‑381 against inflammatory damage of endothelial cells during coronary heart disease by targeting CXCR4.

Authors:  Yimin Li; Jin Huang; Hong Yan; Xiangyu Li; Chang Ding; Qian Wang; Zhiping Lu
Journal:  Mol Med Rep       Date:  2020-01-22       Impact factor: 2.952

9.  The procoagulant activity of tissue factor expressed on fibroblasts is increased by tissue factor-negative extracellular vesicles.

Authors:  Marcela Rosas; David A Slatter; Samya G Obaji; Jason P Webber; Jorge Alvarez-Jarreta; Christopher P Thomas; Maceler Aldrovandi; Victoria J Tyrrell; Peter V Jenkins; Valerie B O'Donnell; Peter W Collins
Journal:  PLoS One       Date:  2020-10-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.